Patents · October 19, 2026
Pharmaceutical Patent vs. FDA Exclusivity: What Is the Difference for Irvine, CA Drug Companies?
The difference between a patent and FDA exclusivity is that a patent is a property right granted by the USPTO, while FDA exclusivity is a statutory delay on approving competing drugs that attaches when FDA approves a product. Patent vs FDA exclusivity planning matters because the two can overlap or run separately. Learn about patent protection or patent law in Irvine, CA.
Patent vs FDA Exclusivity: What Is the Difference?
A patent is a property right granted by the U.S. Patent and Trademark Office, while FDA exclusivity is a period during which FDA delays or bars approval of certain competing drug applications. FDA explains that patents can be issued or expire at any time during development, regardless of whether a drug is approved, while exclusivity attaches only when a drug is approved and meets the statutory requirements. The two are governed by different laws and may or may not cover the same aspects of a product. A patent can be enforced in court against anyone who makes, uses, or sells the claimed invention. Exclusivity, by contrast, works through the approval process and does not depend on any patent. Some drugs have both forms of protection, some have only one, and some have neither.
What Types of FDA Exclusivity Are Available and How Long Do They Last?
FDA lists several types of exclusivity for drugs approved under new drug applications, and each has its own length and eligibility rules. The most valuable for a new molecule is new chemical entity exclusivity, while smaller companies working on rare diseases often focus on orphan drug exclusivity. Pediatric exclusivity does not stand alone but adds six months to existing patents and exclusivities. Biologics follow a separate system under the Public Health Service Act, described later in this article. The figures below come from FDA’s patents and exclusivity FAQ and its biosimilars guidance, and each period starts at approval or licensure rather than at the patent filing date. Because eligibility depends on the specific data and indication, companies typically confirm the likely exclusivity during development rather than after approval.
- New chemical entity (NCE): 5 years
- New clinical investigation: 3 years
- Orphan drug: 7 years
- Pediatric: 6 months added to existing protection
- GAIN for qualifying antibiotics: 5 years added to certain exclusivities
- Biologic reference product: 12 years from first licensure
How Long Does a Drug Patent Last and Can It Be Extended?
A new U.S. patent generally lasts 20 years from its earliest nonprovisional filing date, but drug patents often lose years of useful life during clinical trials and FDA review. To offset part of that loss, 35 U.S.C. 156 allows a patent term extension for one patent per approved product. The extension is based on the regulatory review period, may not exceed five years, and is reduced if the remaining patent term after approval plus the extension would exceed 14 years. The application must be filed within 60 days of the date the product received permission for commercial marketing. Separately, patent term adjustment under 35 U.S.C. 154(b) can add days for certain USPTO delays during examination. Choosing which patent to extend is a strategic decision that depends on claim scope and expiration dates.
How Does the Hatch-Waxman Act Connect Patents and Exclusivity?
The Drug Price Competition and Patent Term Restoration Act of 1984, known as Hatch-Waxman, created the modern framework that links drug patents to FDA’s approval process for generics and also created patent term extension. Brand companies list drug substance, drug product, and method-of-use patents in the Orange Book, and generic applicants must address each listed patent. A generic company that files a Paragraph IV certification claims the patent is invalid, unenforceable, or not infringed. According to FDA, if the patent owner sues within 45 days of notice, approval is generally postponed for 30 months. The first qualifying generic applicant may earn 180 days of exclusivity. These patent-based delays run alongside FDA exclusivity periods, so a product’s actual market protection depends on whichever barrier lasts longest. For more on the patents themselves, see how drug companies protect new formulations.
How Does Biologic Exclusivity Work Under the Purple Book?
Biologics such as antibodies, cell therapies, and therapeutic proteins receive reference product exclusivity under the Biologics Price Competition and Innovation Act rather than the Hatch-Waxman system. According to FDA, a biosimilar application may not be submitted until 4 years after the reference product was first licensed, and approval may not take effect until 12 years after first licensure. Pediatric exclusivity can add time, and orphan exclusivity can also block approval for a protected indication. FDA publishes licensed biologics, biosimilars, interchangeable products, and applicable exclusivity dates in the Purple Book, a searchable online database. Patent disputes for biologics follow a separate process under the same law, and biologics appear in the Purple Book rather than the Orange Book. For biotech companies, the 12-year period can outlast patents that face eligibility or enablement challenges.
Can a California Drug Company Have FDA Exclusivity Without a Patent?
Yes, a California drug company can receive FDA exclusivity even if it has no patent, because exclusivity attaches at approval when the statutory requirements are met. FDA notes that some drugs have both patent and exclusivity protection, while others have just one or neither. This can matter for companies in Irvine and across Orange County developing older molecules, rare disease products, or new indications where patent coverage is limited. Exclusivity has limits, though. It only restricts certain FDA approvals, it cannot be enforced in court against infringers, and it does not cover unapproved uses. A patent, by contrast, can block competitors regardless of FDA status but can be challenged as invalid. Many companies plan both protections together, filing patent applications early while mapping which exclusivities the clinical program may support.
Where Can You Get Help With Patent and FDA Exclusivity Planning in Irvine, CA?
Help with patent and FDA exclusivity planning in Irvine, CA usually begins with mapping your patent filings against your development and approval timeline. mjIP is an Irvine intellectual property law firm founded in 2010 by a USPTO-registered patent attorney who earned a biology degree and previously worked in-house at a Fortune 500 pharmaceutical company in Orange County. The firm assists biotech, pharmaceutical, and supplement companies with patent prosecution in Irvine, CA, from provisional filings through utility applications and related IP questions. Fees are discussed during a free consultation. To schedule one, contact the firm or call (949) 833-7125. Regulatory filings with FDA may also require coordination with regulatory counsel or consultants. This article is general information, not legal advice, and reading it does not create an attorney-client relationship.
Common Questions
Frequently Asked Questions About Patent vs FDA Exclusivity in Irvine, CA
A patent is a property right granted by the USPTO that can be issued at any time during development and enforced in court. FDA exclusivity is a statutory delay or bar on approving certain competing applications, and it attaches only when FDA approves a drug that meets the requirements. The two follow different laws, can run at the same time or separately, and may cover different aspects of a product.
New chemical entity exclusivity lasts 5 years from approval for a drug containing an active moiety FDA has not previously approved. During that time, FDA generally cannot accept certain competing generic and 505(b)(2) applications, with an earlier filing window available for applications that challenge a listed patent. It runs separately from any patent, so a company may benefit even if its compound patent is weak or has expired.
Orphan drug exclusivity lasts 7 years and blocks FDA approval of the same drug for the same rare disease or condition, subject to exceptions such as a showing of clinical superiority. It does not block a different drug for the same disease or the same drug for a different indication. Companies often pair orphan exclusivity with method-of-use patents to strengthen protection for a specific use.
Yes. A patent term extension under 35 U.S.C. 156 can restore up to five years of patent life lost to regulatory review, while FDA exclusivity runs from approval under separate rules. Both may apply to the same product at the same time. The extension is limited to one patent per regulatory review period and must be requested within 60 days of marketing approval.
A reference biologic receives 12 years of exclusivity from first licensure, and a biosimilar application cannot be submitted until 4 years after that date, according to FDA. Pediatric exclusivity can extend the period by six months. FDA lists these dates in the Purple Book, its online database of licensed biological products, which replaced the earlier separate lists.
No. FDA explains that pediatric exclusivity does not stand alone. It adds six months to existing patents and exclusivities that already protect the drug. A company earns it by completing pediatric studies FDA has requested. In the Orange Book, a patent with pediatric exclusivity appears twice, once with its original expiration date and once with the extended date.